Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States.
The last earnings update was 47 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Chimerix. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Chimerix's earnings available for a low price, and how does
this compare to other companies in the same industry?
Chimerix is not considered high growth as it is expected to be loss making for the next 1-3 years.
Chimerix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Chimerix's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Michael A. Sherman, also known as Mike, has been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 and serves as President its since 2019. Mr. Sherman served as the Chief Executive Officer and President of Endocyte, Inc. since June 20, 2016. Mr. Sherman served as the Chief Financial Officer of Endocyte, Inc. since October 11, 2006 until February 2017 and its Chief Operating Officer since June 16, 2014 until June 20, 2016. He served as the Principal Accounting Officer of Endocyte, Inc., until May 26, 2011. Mr. Sherman served as a Director of Finance at Guidant Sales Corporation from March 1997 to March 2000. While at Guidant, he served several senior management positions, including Vice President for Finance and IT, Europe, Middle East, Africa and Canada and Corporate Controller and Chief Accounting Officer. He served as a Director for Corporate Financial Planning from 1994 to March 1997. He served positions in audit, domestic and international financial planning and reporting, business development and treasury while with Lilly and served as VP Finance and Strategic Planning at Guidant LLC from May 2004 to October 2006. He was a Director of Endocyte, Inc. since June 20, 2016 until December 21, 2018. He served as a Director of Mead Johnson Nutrition Company from February 26, 2015 to June 15, 2017. Mr. Sherman serves on the Indianapolis Children’s Museum Board of Trustees. He received his Masters in Business Administration from The Amos Tuck School at Dartmouth University and Graduated as a Tuck Scholar. Mr. Sherman holds a B.A. in Economics from DePauw University.
Insufficient data for Mike to compare compensation growth.
Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Chimerix management team is about average.
Chief Medical Officer
CEO & President
Chief Manufacturing & Technology Officer
Chief Science Officer
VP of Information Technology & Chief Information Officer
Executive Director of Financial Planning
Senior VP & General Counsel
Chief Business Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Chimerix board of directors is about average.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.